Cargando…
A Chinese patient with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin
At present, approximately 20% of Hodgkin lymphomas (HL) are relapsed and refractory, and therapeutic methods including chemotherapy, radiotherapy, and even stem cell transplantation are unsatisfactory. Brentuximab vedotin, composed of CD30 antibody and a chemotherapeutic agent, is a new targeted dru...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Sun Yat-sen University Cancer Center
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845561/ https://www.ncbi.nlm.nih.gov/pubmed/23544448 http://dx.doi.org/10.5732/cjc.012.10221 |